Table 1.
Clinical characteristics of the study groups.
| Untreated Group without PN (n = 59) |
Treated Group with PN (n = 34) |
Treated Group without PN (n = 27) |
p-Value * Treated Group with PN vs. Untreated Group without PN |
p-Value * Treated Group without PN vs. Untreated Group without PN |
p-Value * Treated Group with PN vs. Treated Group without PN |
|
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ±SD | ||||
| Patient’s age (years) | 63.13 ± 9.74 | 65.73 ± 7.76 | 62.59 ± 9.74 | 0.2828 | 0.8412 | 0.2787 |
| Sex (male/female) | 29/30 | 22/12 | 19/8 | 0.1210 | ||
| White Blood Cells (×103/µL) | 7.25 ± 3.24 | 6.47 ± 2.57 | 5.33 ± 2.69 | 0.3129 | 0.0007 | 0.0125 |
| Platelets (×103/µL) | 236.30 ± 97.22 | 215.11 ± 103.08 | 215.59 ± 97.66 | 0.2268 | 0.3520 | 0.8902 |
| Erythrocytes (mln/mm3) | 3.54 ± 0.70 | 3.73 ± 0.50 | 3.73 ± 0.54 | 0.4279 | 0.2584 | 0.9272 |
| Hemoglobin (g/dL) | 10.94 ± 2.19 | 11.68 ± 1.80 | 11.94 ± 1.23 | 0.1168 | 0.0319 | 0.5759 |
| Hematocrit (%) | 32.13 ± 6.27 | 35.10 ± 3.76 | 35.45 ± 3.72 | 0.1726 | 0.0204 | 0.5837 |
| MCV (fL) | 90.69 ± 4.46 | 94.35 ± 4.78 | 95.68 ± 8.17 | 0.0392 | 0.0057 | 0.9708 |
| MPV (fL) | 10.18 ± 0.93 | 10.68 ± 1.36 | 9.97 ± 0.97 | 0.3089 | 0.3521 | 0.0947 |
| Total Ca2+ (mmol/L) | 2.34 ± 0.38 | 2.28 ± 0.05 | 2.27 ± 0.23 | 0.6237 | 0.9101 | 0.5116 |
| Total protein (g/dL) | 8.21 ± 2.07 | 6.95 ± 1.74 | 6.72 ± 0.94 | 0.0005 | 0.0006 | 0.4899 |
| IgG (g/L) | 25.30 ± 25.97 | 16.35 ± 17.92 | 5.9 ± 3.84 | 0.4085 | 0.1860 | 0.1775 |
| IgA (g/L) | 8.72 ± 16.79 | 3.79 ± 10.85 | 0.29 ± 0.21 | 0.9382 | 0.3750 | 0.1349 |
| IgM (g/L) | 0.31 ± 0.34 | 0.38 ± 0.23 | 0.25 ± 0.22 | 0.0335 | 1.000 | 1 |
| FLCs kappa (mg/dL) | 210.90 ± 272.85 | 143.27 ± 261.15 | 143.02 ± 291.30 | 0.1611 | 0.2517 | 0.8084 |
| FLCs lambda (mg/dL) | 130.56 ± 284.7 | 27.02 ± 60.38 | 21.14 ± 37.21 | 0.8770 | 0.8643 | 0.7959 |
* Mann–Whitney test except sex (Pearson’s chi-squared test). In bold, p-values < 0.05.